Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial

In This Article:

Novo Nordisk's (NVO) said Friday that its investigative weight loss drug, amycretin, led to a body w

Upgrade to read this MT Newswires article and get so much more.
A Silver or Gold subscription plan is required to access premium news articles.